A Patel

Dr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.au

STUDY DESIGN

Design:

randomised controlled trial (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation [ADVANCE]).

Allocation:

concealed.*

Blinding:

blinded (outcome assessors, {patients, clinicians, data collectors, data analysts, and manuscript writers}).*†

STUDY QUESTION

Setting:

215 centres in 20 countries in Asia, Australasia, Europe, and North America.

Patients:

11 140 patients ⩾55 years of age (mean age 66 y, 57% men) who were diagnosed with type 2 diabetes mellitus at ⩾30 years of age and had ⩾1 of the following: history of major cardiovascular disease or risk factor for cardiovascular disease (ie, history of major microvascular disease, current cigarette smoking, total cholesterol >6.0 mmol/l, high-density lipoprotein cholesterol <1.0 mmol/l, urinary albumin-creatinine ratio 30–300 μg/mg, diagnosis of type 2 diabetes ⩾10 years previously, or age ⩾65 y). Exclusion criteria included definite indication for an angiotensin-converting enzyme inhibitor other …